Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

May 11 2021

- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

- Completed initial public offering of ADSs raising $175.5 million in gross proceeds -        

LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.

“Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end,” said Dr Iraj Ali, Chief Executive Officer of Achilles. “We continue to enroll and dose patients and have opened our first clinical sites in the US and EU. This year, we expect to report interim data from a total of ten patients that have received cNeT monotherapy across the CHIRON and THETIS trials and will also begin enrolling patients to receive higher dose cNeT. In addition, we will open Cohort B in the THETIS study to evaluate the addition of a PD-1 inhibitor to our cNeT therapy.”

Business Highlights

  • Received a recommendation from the Independent Data Safety Monitoring Committee to continue the ongoing Phase I/IIa CHIRON and THETIS trials as planned
  • Announced initial clinical data from the first six patients dosed with the Company’s cNeT therapy showing encouraging evidence of cNeT engraftment, an overall tolerability profile similar to that of standard TIL products, stable disease in four out of the six patients, and one patient with tumor lesion reduction
  • Presented data at the American Association of Cancer Research (AACR) annual meeting detailing the Company’s comprehensive translational research program and insights into the in vivo dynamics of cNeT post-dosing, and the potential to develop a potency-based release assay
  • Strengthened the Board of Directors and Scientific Advisory Board with the additions of Julie O’Neill and Markwin Velders, Ph.D., respectively, and continued to build the team in the UK & US, including key appointments across manufacturing, supply chain and clinical operations, bio-processing and intellectual property
  • Received a Horizon 2020 grant as part of the Neoantigen Consortium, with the aim of developing a tool to predict neoantigen immunogenicity.

Financial Highlights

  • IPO: Priced an initial public offering of 9,750,000 ADRs at a public offering price of $18.00 per share for gross proceeds of $175.5 million. The IPO closed on April 6, 2021, after the quarter end.
  • Cash and cash equivalents: Cash and cash equivalents were $159.3 million as of March 31, 2021 as compared to $177.8 million as of December 31, 2020, not including $160.6 million in net proceeds from the IPO which closed on April 6, 2021. The Company anticipates that its existing cash and cash equivalents plus the IPO proceeds are sufficient to fund its planned operations into the second half of 2023, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.
  • Operating Expenses: Operating Expenses were $13.7 million for the quarter ended March 31, 2021, which included $8.9 million in Research & Development, and General and Administrative expenses of $4.8 million.
  • Net loss: Net loss attributable to ordinary shareholders was $13.8 million for the quarter ended March 31, 2021 and the basic and diluted net loss per ordinary share was $8.38 for the quarter ended March 31, 2021.

Upcoming Events

  • Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference at on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.
  • A poster detailing abstract TPS9138 entitled, An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Clonal Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON), will be presented at the 2021 ASCO Annual Meeting taking place virtually from June 4-9, 2021. Full abstracts will be released on May 19, 2021 at

About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Forward-Looking Statements

This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Further information:

Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000


Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)

    March 31,     December 31,  
    2021     2020  
Current assets:                
Cash and cash equivalents   $ 159,262     $ 177,849  
Prepaid expenses and other current assets     14,058       9,948  
Total current assets     173,320       187,797  
Non-current assets:                
Property and equipment, net     15,479       13,369  
Operating lease right of use assets     14,155       14,740  
Deferred tax assets     4       4  
Other assets     3,145       3,008  
Total non-current assets     32,783       31,121  
TOTAL ASSETS   $ 206,103     $ 218,918  
Current liabilities:                
Accounts payable   $ 1,787     $ 6,314  
Income taxes payable     19       7  
Accrued expenses and other liabilities     8,646       6,590  
Operating lease liabilities-current     4,610       3,712  
Total current liabilities     15,062       16,623  
Non-current liabilities:                
Operating lease liabilities-non-current     11,329       12,271  
Other long-term liability     659       652  
Total non-current liabilities     11,988       12,923  
Total liabilities     27,050       29,546  
Commitments and contingencies (Note 11)                
Shareholders’ equity:                
Ordinary shares, £0.001 par value; 4,371,658 and 4,389,920 shares
authorized, issued and outstanding at March 31, 2021 and December
31, 2020, respectively
    6       6  
Deferred shares, £0.001 par value; 109,058 and 30,521 shares issued and
outstanding as of March 31, 2021 and December 31, 2020, respectively
Convertible preferred shares, £0.001 par value; no shares authorized,
issued and outstanding as of March 31, 2021;104,854,673 shares
authorized, issued and outstanding at December 31, 2020
    134       134  
Additional paid in capital     236,305       234,922  
Accumulated other comprehensive income     14,385       12,322  
Accumulated deficit     (71,777 )     (58,012 )
Total shareholders’ equity     179,053       189,372  


Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share amounts)

    Three Months Ended March 31,  
    2021     2020  
OPERATING EXPENSES:                
Research and development   $ 8,876     $ 3,830  
General and administrative     4,832       1,736  
Total operating expenses     13,708       5,566  
Loss from operations     (13,708 )     (5,566 )
OTHER INCOME (EXPENSE), NET:                
Other income (expense)     (45 )     352  
Total other income (expense), net     (45 )     352  
Loss before provision for income taxes     (13,753 )     (5,214 )
Provision for income taxes     (12 )      
Net loss     (13,765 )     (5,214 )
Other comprehensive income:                
Foreign exchange translation adjustment     2,063       (6,510 )
Comprehensive loss   $ (11,702 )   $ (11,724 )
Net loss per share attributable to ordinary shareholders—basic and diluted   $ (8.38 )   $ (6.13 )
Weighted average ordinary shares outstanding—basic and diluted     1,641,938       850,377  


Print Page
RSS Feeds
Email Alerts
Contact IR